• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Weight response to GLP-1 receptor agonists: Why women do it better?

作者信息

Jensterle Mojca, Rizzo Manfredi, Janež Andrej

机构信息

Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.

School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Italy.

出版信息

J Diabetes Complications. 2022 Nov;36(11):108310. doi: 10.1016/j.jdiacomp.2022.108310. Epub 2022 Sep 17.

DOI:10.1016/j.jdiacomp.2022.108310
PMID:36150366
Abstract
摘要

相似文献

1
Weight response to GLP-1 receptor agonists: Why women do it better?对胰高血糖素样肽-1受体激动剂的体重反应：为何女性效果更佳？
J Diabetes Complications. 2022 Nov;36(11):108310. doi: 10.1016/j.jdiacomp.2022.108310. Epub 2022 Sep 17.
2
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
3
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
4
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.新型降糖药物与二甲双胍联合治疗 2 型糖尿病的心血管疗效的性别差异。
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. doi: 10.1161/JAHA.119.012940. Epub 2020 Jan 4.
5
Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂用于 2 型糖尿病合并晚期慢性肾脏病患者的死亡率相关。
JAMA Netw Open. 2022 Mar 1;5(3):e221169. doi: 10.1001/jamanetworkopen.2022.1169.
6
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
7
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.二肽基肽酶-4 抑制剂与胰高血糖素样肽-1 受体激动剂使用者心力衰竭住院风险的比较。
Cardiovasc Diabetol. 2018 Jul 17;17(1):102. doi: 10.1186/s12933-018-0746-4.
8
The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.GLP-1 类药物在糖尿病管理中的地位：DPP-4 抑制剂与 GLP-1 受体激动剂的差异。
Curr Diab Rep. 2013 Jun;13(3):307-18. doi: 10.1007/s11892-013-0377-9.
9
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.胰高血糖素样肽-1激动剂和二肽基肽酶IV抑制剂。
Handb Exp Pharmacol. 2011(203):53-74. doi: 10.1007/978-3-642-17214-4_3.
10
Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.2 型糖尿病的初级保健管理：胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的疗效和安全性比较。
Postgrad Med. 2021 Nov;133(8):843-853. doi: 10.1080/00325481.2021.1971461. Epub 2021 Sep 12.

引用本文的文献

1
Obesity: Recent Advances and Future Perspectives.肥胖症：最新进展与未来展望
Biomedicines. 2025 Feb 5;13(2):368. doi: 10.3390/biomedicines13020368.
2
Characterizing Brainstem GLP-1 Control of Sensory-Specific Satiety in Male and Female Rats Across the Estrous Cycle.表征发情周期中雄性和雌性大鼠脑干胰高血糖素样肽-1对特定感觉饱腹感的控制。
Biol Psychiatry. 2025 Aug 1;98(3):249-259. doi: 10.1016/j.biopsych.2025.01.012. Epub 2025 Jan 22.
3
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
胰高血糖素样肽-1受体激动剂在射血分数保留的肥胖相关性心力衰竭管理中的新作用：益处超乎体重秤所能衡量？
Biomedicines. 2024 Sep 16;12(9):2112. doi: 10.3390/biomedicines12092112.